Other languages Nuformix plc

Equities

Market Closed - London S.E. Other stock markets 09:05:06 10/05/2024 pm IST			5-day change	1st Jan Change
0.185 ^GBX	0.00%		+5.71%	-43.08%

01/03	Nuformix announces subscription to raise GBP150,000	AN
15/01	Nuformix plc Reports Earnings Results for the Eighteen Months Ended September 30, 2023	CI

Nuformix announces subscription to raise GBP150,000	01/03
Nuformix plc Reports Earnings Results for the Eighteen Months Ended September 30, 2023	15/01
Nuformix narrows annual loss as develops drug assets	03/01
Nuformix plc Reports Earnings Results for the Half Year Ended September 30, 2023	03/01
Nuformix gets patent in Japan for pulmonary fibrosis treatment NXP002	23/23/23
Nuformix Receives Japanese Patent for Pulmonary Fibrosis Treatment; Shares Surge	23/23/23
Nuformix plc Announces Notice of Allowance of NXP002 Patent in Japan	23/23/23
Nuformix Updates Oxilio Agreement for NXP001	18/23/18
Nuformix to receive milestone payments from Oxilio pact	18/23/18
Nuformix plc Receives New NXP001 Development Milestone Payments in Updated Oxilio Agreement	18/23/18
Nuformix loss narrows; near-term goal to focus on NXP002 asset	22/23/22
Nuformix plc Reports Earnings Results for the Full Year Ended March 31, 2023	22/23/22
Nuformix says NXP002 shows anti-inflammatory effect	18/23/18
Nuformix to Launch Partnering Process for Inhaled Lung Disease Drug	18/23/18
Nuformix plc Announces Update Regarding the NXP002 Programme	18/23/18
Nuformix raises GBP70,000 to fund NXP002 programme	17/23/17
Nuformix Plans Equity Raise to Fund Inhaled Treatment Program; Shares Sink 18%	17/23/17
Sabien works with Empiric; Coro sells in Italy	27/23/27
Nuformix plc Announces the Update Regarding the Company's Nxp002 Programme	27/23/27
Nuformix plc Announces Changes to Financial Year End from 31 March to 30 September	13/23/13

No results for this search